One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study
Table 3
VFQ-25 subscale and total scores at 3 and 12 months. Values are shown as mean ± SD.